📌 Key Takeaways
- Topic: Fumed Silica Supplier: How to Evaluate Grades, Consistency and Technical Support
- Keywords: semiconductor grade silica
- Published: 2026-11-20 09:09:23
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
What Is Mesoporous Silica? Structure, Pore Size and Applications in Drug Delivery and Catalysis
- Pharmaceutical Grade Silica: Specifications, USP/EP Standards and Uses as an Excipient
- In the case of melt granulation, it is necessary to use meltable excipients that can melt at low temperatures (50-90 °C) as a binder [ 98, 108 ]. The molten binder forms the agglomerates during cooling and solidification. Since it does not need a liquid binder, it is advantageous for use in the case of moisture-sensitive molecules. However, its use should be avoided for heat-sensitive materials.
- Fumed Silica vs Precipitated Silica: Differences in Production, Properties and Uses
- 48. Szegedi Á., Trendafilova I., Mihály J., Lázár K., Németh P., Momekov G., Momekova D., Marinov L., Nikolova I., Popova M. New insight on prednisolone polymorphs in mesoporous silica/maghemite nanocomposites. J. Drug Deliv. Sci. Technol. 2020;60:102092. doi: 10.1016/j.jddst.2020.102092. [ DOI ] [ Google Scholar ]
- Silica for UV Adhesive: Rheology Control and Transparency Considerations
- The potential of MSNs may also be utilized well in the case of polypills. In this case, all drugs must be dissolved in the solvent. After that, the carriers must be loaded with this complex solution, employing one of the already mentioned drug loading techniques. This can be followed by tableting nanocarriers. This approach can be really beneficial in the treatment of hypertension, where combination therapy is most often used. Patient compliance could also be improved with the production of such a polypill, since taking one pill rather than multiple pills may be simpler for the combined treatment of high blood pressure [ 99 ].
- Cab-O-Sil M-5: Specifications, Uses and Equivalent Fumed Silica Grades
- This equation fits especially well for premature release, up to 60% of the drug released, when there is no change in the matrix system during the release process. From a perspective of pore geometry, it basically controls drug release rates by affecting effective diffusion pathways. Boosted complexity of geometries raises tortuosity and reduces effective diffusion. High tortuosity and low pore connectivity cut down drug diffusion, consequently lowering the release rates. Furthermore, surface roughness and pore size distribution affect surface region, diffusion, and residence times, and thereby drug release kinetics. Thus, coupling the Fick diffusion model with parameters characterizing pore geometry (e.g., porosity, tortuosity, etc.) enables for more precise and automatic modeling of drug release kinetics. In this way, it is nicely clarified why release profiles differ for chemically comparable matrices due to differences in their geometrical shapes [ 59, 60 ].
What Is Spherical Silica? Benefits, Specifications and Uses in Semiconductor Packaging
What is silica (SiO₂)?
silica surface area Ho et al. employed the Multiple-Path Particle Dosimetry (MPPD) model for aerosolization and determination of lung deposition of silver nanoparticles, which method may be broadened to other materials like mesoporous silica nanoparticles [ 87 ]. It suggests particle size (mean 18 nm), density, and generation approach as principal elements that determine aerosolization efficiency and inhaled dose. Simulations of airflow, diffusion, sedimentation, and impact through airway generations yield comparable alveolar deposition fractions for particles less than 100 nm in humans and rats. With the addition of species-specific parameters, such as respiratory rate, lung surface region, tidal volume, and finished with possible lobar- and airway-level analysis, the MPPD model makes realistic regional retention predictions. Given that mesoporous silica nanoparticles are of similar size and physicochemical properties, the same methodology can estimate their aerosolization and lung deposition. In summary, the MPPD model is a handy tool in the assessment of inhalation danger and in guiding the formulation of safer nanomaterials [ 87 ]. In another study, Ali et al. applied the MPPD model to simulate aerosolization and lung deposition of mesoporous silica nanoparticles [ 88 ]. Pre-characterized MSNs with pre-specified aerodynamic diameters were initially assessed through scanning mobility particle sizing to yield accurate size-distribution inputs. Asymmetric mouse airway geometry and physiological parameters such as respiratory rate, lung volume, and airflow were used in simulations that were approximated to provide a total lung deposition of about 45%, of which 37% was in the head, 27% in the tracheobronchial, and 36% in the pulmonary (alveolar) region. These predictions are in reasonable agreement with earlier in vivo findings, validating the model. MPPD analysis also indicated that smaller MSNs exhibit more alveolar deposition, with the larger particles being better in the upper airways. Through linking aerosolization efficiency (via size distribution and concentration) and regional deposition, this modeling approach orients optimization of nanoparticle size and generation techniques toward maximizing targeted lung delivery [ 88 ]. To achieve easier production of aerosols, the surface of nanoparticles is often provided with a polymer coating, thereby stabilizing their distribution and increasing dispersibility [ 56 ]. By lowering the particle size, deeper lung areas can be reached [ 25 ]. Particles smaller than 1 µm are capable of accumulating in the alveoli, but the ideal size range to achieve maximum efficiency is in the 200-500 nm range [ 25 ]. Nevertheless, another review cited that particle size in the range of 50-200 nm is ideal for maximizing drug localization by inhalation [ 89 ]. It has also been recommended that the perfect diameter is approximately 500 nm for phagocytosis by alveolar macrophages [ 89 ]. Li et al. nebulized PEI-PEG-coated MSNs (50 nm particle size) by standard nebulizers without compromising their structure, while keeping particles in their individual form within the water droplets [ 90 ]. The aerosol supplies convenient delivery of MSNs to all areas of the respiratory tract - nasal, tracheobronchial, and pulmonary - and they persist for a week following inhalation, mostly within alveolar macrophages. It offers intracellular targeted delivery of lung diseases without passing through the gastrointestinal and first-pass metabolism. In spite of decreased deep lung deposition in mice under nasal breathing, exposure is comparable to that of humans with inhalation. Toxicity tests revealed no tissue damage or inflammation, further supporting MSN inhalation as a safe and effective method for vast treatment of pulmonary diseases, feasible for clinical translation [ 90 ]. A study investigated the effect of surface chemistry on drug loading capacity, release kinetics, and antibiotic activity in pulmonary infections on S. aureus bacterial cultures [ 18 ]. The model drugs were isoniazid, rifampicin, and vancomycin. Remarkable absorption ability was observed only with thiol (-SH) grafted carriers for all the tested drugs [ 18 ]. The in vitro drug release study showed sustained, but limited release: the cumulative release of rifampicin was 78.5% after 12 days, estimated by antibiogram [ 18 ]. Interestingly, the MIC values of the MSN-drug complex were higher for the free drug, probably due to the delayed and incomplete release from the pores [ 18 ]. Wang et al. developed a polydopamine-coated MSN formulation co-loaded with Ziyuglycoside I and Oseltamivir for the treatment of viral pneumonia. Interestingly, in vitro and in vivo studies have demonstrated that this carrier provided immediate release of Oseltamivir (allows quick virus killing) but prolonged release of Ziyuglycoside I (cuts down the inflammatory response for a longer period) [ 62 ].
What is the difference between fumed silica and precipitated silica?
silica sand for glass 5. Drug Release
What drives silica raw material prices?
silicon dioxide common name Mesoporous silica nanocarriers (MSNs) have emerged as considerable candidates in the pharmaceutical industry for drug delivery systems, suitable for a wide range of drugs. Absorbing the active pharmaceutical ingredients (APIs) into the pores can be handy in several ways. The narrow pores may stabilize the APIs in an amorphous state, thereby boosting its aqueous solubility and supplying protection for the encapsulated drug against various takes into consideration the human body, such as enzymatic or chemical degradation, which boosts the bioavailability of the product. Beside the overview of their main traits, the present review focuses on the recent findings on MSNs form therapeutic and drug formulation perspective, such as functionalization possibilities, as the size and surface of the particles influence the interactions with the cell membrane; therefore, the epithelial permeability of and release rate from the carrier, and may offer even targeted delivery in an organ-, tissue- or cell-specific manner, improving the therapy, also steering clear of drug-related side impacts.
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.